Healthy
Conditions
Brief summary
This study is being conducted to determine how safe and how well tolerated LY3462817 is when given intravenously (IV) (into a vein) and subcutaneously (SC) (just under the skin) to healthy participants. Blood tests will be done to check how much LY3462817 is in the bloodstream and how long the body takes to get rid of it. Each enrolled participant will receive 1 dose of LY3462817 or placebo. The study will last about 16 weeks, including screening.
Interventions
BIOLOGICALLY3462817 IV
Administered IV
BIOLOGICALLY3462817 SC
Administered SC
DRUGPlacebo
Administered IV
Sponsors
Eli Lilly and Company
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
21 Years to 70 Years
Healthy volunteers
Yes
Inclusion criteria
* Overtly healthy male or a female who cannot get pregnant * Have a body mass index (BMI) of 18 to 32 kilogram per square meter (kg/m²), inclusive, at screening * Have normal blood pressure, pulse rate, electrocardiogram (ECG, heart tracing), blood and urine laboratory test results that are acceptable for the study * Weight at least 45 kilograms (kg)
Exclusion criteria
* Are currently participating in or completed a clinical trial within the last 30 days or any other type of medical research judged to be incompatible with this study * Have previously participated or withdrawn from this study * Have cancer or a malignant disease in the past 5 years * Have or used to have health problems or laboratory test results or ECG readings that, in the opinion of the doctor, could make it unsafe to participate, or could interfere with understanding the results of the study * Are unwilling to receive study drug administration by injections or through the veins
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug | Baseline through to final follow-up at approximately Week 12 | A summary of SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Pharmacokinetics: Maximum Concentration (Cmax) of LY3462817 | Baseline through to final follow-up at approximately Week 12 | Pharmacokinetics: Cmax of LY3462817 |
| Pharmacokinetics: Area Under the Concentration Versus Time Curve (AUC) of LY3462817 | Baseline through to final follow-up at approximately Week 12 | Pharmacokinetics: AUC of LY3462817 |
Countries
Singapore
Outcome results
None listed